Hypoglycemia in Patients With LAMA2-CMD
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
PEDIATRIC NEUROLOGY, v.143, p.1-5, 2023
Resumo
Background: Hypoglycemia has been reported in patients with LAMA2-CMD, but the frequency, risk factors, and correlation to genotype/phenotype have not been systematically assessed to date. Methods: A retrospective cohort study was performed on 48 patients with LAMA2-CMD. Patients were divided into two groups: a hypoglycemic group, with at least one episode of hypoglycemia, and a nonhypoglycemic group. The groups were compared according to gait function, epilepsy, intellectual disability, constipation, gastroesophageal reflux, gastrostomy, weight percentile, scoliosis, the use of a ventilator device, the use of a feeding device, neuromuscular disease swallowing status scale, and type of mutation. Results: Fifteen patients (31.2%) presented with at least one episode of symptomatic hypoglycemia and eight (16.6% of the cohort) had two or more episodes. All patients who had hypoglycemia were in the nonambulant group. We observed a correlation between gait, the use of ventilator and feeding devices, and swallow function with hypoglycemia. Patients with extremely low weight were five times more likely to have recurrent episodes of hypoglycemia. The presence of at least one missense variant appears to be associated with a lower risk of hypoglycemia. Conclusion: Patients with LAMA2-CMD are at risk of hypoglycemia. The risk is more relevant in patients with severe phenotype and patients with loss-of-function variants. For patients with extremely low weight, the risk is higher. Blood glucose should be actively measured in patients who are fasting or have infections, and health care providers should be prepared to identify and treat these patients. (c) 2023 Published by Elsevier Inc.
Palavras-chave
LAMA2-CMD, Hypoglycemia, Genotype -phenotype, Weight
Referências
- Bonnemann CG, 2014, NEUROMUSCULAR DISORD, V24, P289, DOI 10.1016/j.nmd.2013.12.011
- BRUCE AK, 1995, LANCET, V346, P609
- Darin N, 2000, NEUROMUSCULAR DISORD, V10, P1, DOI 10.1016/S0960-8966(99)00055-3
- de Oliveira BM, 2014, MOL CELL PROTEOMICS, V13, P3001, DOI 10.1074/mcp.M113.032276
- Fontes-Oliveira CC, 2017, SCI REP-UK, V7, DOI 10.1038/srep45272
- Geranmayeh F, 2010, NEUROMUSCULAR DISORD, V20, P241, DOI 10.1016/j.nmd.2010.02.001
- Graziano A, 2015, NEUROLOGY, V84, P904, DOI 10.1212/WNL.0000000000001303
- Hayes LH, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-1909-5
- Katsetos CD, 2013, SEMIN PEDIATR NEUROL, V20, P202, DOI 10.1016/j.spen.2013.10.010
- Koopman R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00032
- Oliveira J, 2008, CLIN GENET, V74, P502, DOI 10.1111/j.1399-0004.2008.01068.x
- Oliveira J, 2012, GENEREVIEWS, P1993
- Philpot J, 1999, ARCH DIS CHILD, V80, P542, DOI 10.1136/adc.80.6.542
- Reed UC, 2009, ARQ NEURO-PSIQUIAT, V67, P144, DOI 10.1590/S0004-282X2009000100038
- SHU SG, 1989, BRAIN DEV-JPN, V11, P62, DOI 10.1016/S0387-7604(89)80011-7
- Sunehag AL, 2001, PEDIATR RES, V50, P115, DOI 10.1203/00006450-200107000-00021
- Wada A, 2015, J NEUROL, V262, P2225, DOI 10.1007/s00415-015-7836-y